Nurix Therapeutics (NRIX) Cash from Operations Growth (3y) (2022 - 2026)
Powered by 
Analysis
Nurix Therapeutics (NRIX) Cash from Operations Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -0.27% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -7.35% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 16.85% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 52.90% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 96.08% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 6.22% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 10.23% |
| 10 | Nurix Therapeutics | 2.86 Bn | 2.42 Bn | - | -73.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -73.57% |
| Feb 28, 2026 | -14.07% |
| Nov 30, 2025 | -21.35% |
| Aug 31, 2025 | -7.41% |
| May 31, 2025 | -24.27% |
| Feb 28, 2025 | -12.74% |
| Nov 30, 2024 | -16.40% |
| Aug 31, 2024 | -12.06% |
| May 31, 2024 | -7.98% |
| Feb 29, 2024 | -93.18% |
| Nov 30, 2023 | 48.93% |
| Aug 31, 2023 | -88.50% |
| May 31, 2023 | -8.58% |
| Feb 28, 2023 | -47.09% |
| Nov 30, 2022 | -43.86% |